{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:46:11Z","timestamp":1790707571267,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T00:00:00Z","timestamp":1620172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T00:00:00Z","timestamp":1620172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005690","name":"Universit\u00e4t des Saarlandes","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005690","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Phys"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Dosimetry is of high importance for optimization of patient-individual PSMA-targeted radioligand therapy (PSMA-RLT). The aim of our study was to evaluate and compare the feasibility of different approaches of image-based absorbed dose estimation in terms of accuracy and effort in clinical routine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Whole-body planar images and SPECT\/CT images were acquired from 24 patients and 65 cycles at 24h, 48h, and \u226596h after administration of a mean activity of 6.4 GBq [<jats:sup>177<\/jats:sup>Lu]Lu-PSMA-617 (range 3\u201310.9 GBq). Dosimetry was performed by use of the following approaches: 2D planar-based dosimetry, 3D SPECT\/CT-based dosimetry, and hybrid dosimetry combining 2D and 3D data. Absorbed doses were calculated according to IDAC 2.1 for the kidneys, the liver, the salivary glands, and bone metastases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Mean absorbed doses estimated by 3D dosimetry (the reference method) were 0.54 \u00b1 0.28 Gy\/GBq for the kidneys, 0.10 \u00b1 0.05 Gy\/GBq for the liver, 0.81 \u00b1 0.34 Gy\/GBq for the parotid gland, 0.72 \u00b1 0.39 Gy\/GBq for the submandibular gland, and 1.68 \u00b1 1.32 Gy\/GBq for bone metastases. Absorbed doses of normal organs estimated by hybrid dosimetry showed small, non-significant differences (median up to 4.0%) to the results of 3D dosimetry. Using 2D dosimetry, in contrast, significant differences (median up to 10.9%) were observed. Regarding bone metastases, small, but significant differences (median up to 7.0%) of absorbed dose were found for both, 2D dosimetry and hybrid dosimetry. Bland-Altman analysis revealed high agreement between hybrid dosimetry and 3D dosimetry for normal organs and bone metastases, but substantial differences between 2D dosimetry and 3D dosimetry.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Hybrid dosimetry provides high accuracy in estimation of absorbed dose in comparison to 3D dosimetry for all important organs and is therefore feasible for use in individualized PSMA-RLT.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40658-021-00385-4","type":"journal-article","created":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T09:05:37Z","timestamp":1620205537000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy"],"prefix":"10.1186","volume":"8","author":[{"given":"Florian","family":"Rosar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Sch\u00f6n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Bohnenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bartholom\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Stemler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Maus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Khreish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Ezziddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2439-5786","authenticated-orcid":false,"given":"Andrea","family":"Schaefer-Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,5]]},"reference":[{"issue":"6","key":"385_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","journal-title":"CA Cancer J Clin."},{"issue":"11","key":"385_CR2","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","volume":"65","author":"M Kirby","year":"2011","unstructured":"Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review: the epidemiology of CRPC. Int J Clin Pract. 2011;65(11):1180\u201392. https:\/\/doi.org\/10.1111\/j.1742-1241.2011.02799.x.","journal-title":"Int J Clin Pract."},{"issue":"12","key":"385_CR3","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc4016","volume":"15","author":"PA Watson","year":"2015","unstructured":"Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015;15(12):701\u201311. https:\/\/doi.org\/10.1038\/nrc4016.","journal-title":"Nat Rev Cancer."},{"issue":"2","key":"385_CR4","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","volume":"26","author":"DR Berthold","year":"2008","unstructured":"Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26(2):242\u20135. https:\/\/doi.org\/10.1200\/JCO.2007.12.4008.","journal-title":"J Clin Oncol."},{"issue":"15","key":"385_CR5","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, Horti J, Oudard S, James ND, Rosenthal MA. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502\u201312. https:\/\/doi.org\/10.1056\/NEJMoa040720.","journal-title":"N Engl J Med."},{"issue":"2","key":"385_CR6","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1209096.","journal-title":"N Engl J Med."},{"issue":"5","key":"385_CR7","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1405095.","journal-title":"N Engl J Med."},{"issue":"1","key":"385_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2967\/jnumed.116.183194","volume":"58","author":"K Rahbar","year":"2017","unstructured":"Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Sch\u00e4fers M, Essler M, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58(1):85\u201390. https:\/\/doi.org\/10.2967\/jnumed.116.183194.","journal-title":"J Nucl Med."},{"issue":"7","key":"385_CR9","doi-asserted-by":"publisher","first-page":"955","DOI":"10.2967\/jnumed.118.216820","volume":"60","author":"TW Barber","year":"2019","unstructured":"Barber TW, Singh A, Kulkarni HR, Niepsch K, Billah B, Baum RP. Clinical outcomes of 177Lu-PSMA radioligand therapy in earlier and later phases of metastatic castration-resistant prostate cancer grouped by previous taxane chemotherapy. J Nucl Med. 2019;60(7):955\u201362. https:\/\/doi.org\/10.2967\/jnumed.118.216820.","journal-title":"J Nucl Med."},{"issue":"7","key":"385_CR10","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1097\/RLU.0000000000001240","volume":"41","author":"K Rahbar","year":"2016","unstructured":"Rahbar K, Bode A, Weckesser M, Avramovic N, Claesener M, Stegger L, et al. Radioligand therapy with 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration resistant prostate cancer. Clin Nucl Med. 2016;41(7):522\u20138. https:\/\/doi.org\/10.1097\/RLU.0000000000001240.","journal-title":"Clin Nucl Med."},{"issue":"8","key":"385_CR11","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.2967\/jnumed.115.171397","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Giesel FL, Stefanova M, Bene\u0161ov\u00e1 M, Bronzel M, Afshar-Oromieh A, et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617. J Nucl Med. 2016;57(8):1170\u20136. https:\/\/doi.org\/10.2967\/jnumed.115.171397.","journal-title":"J Nucl Med."},{"issue":"6","key":"385_CR12","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","volume":"19","author":"MS Hofman","year":"2018","unstructured":"Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19(6):825\u201333. https:\/\/doi.org\/10.1016\/S1470-2045(18)30198-0.","journal-title":"Lancet Oncol."},{"issue":"Suppl10","key":"385_CR13","first-page":"S13","volume":"6","author":"SS Chang","year":"2004","unstructured":"Chang SS. Overview of prostate-specific membrane antigen. Rev Urol. 2004;6(Suppl10):S13\u20138.","journal-title":"Rev Urol."},{"issue":"7","key":"385_CR14","first-page":"1807","volume":"54","author":"RS Israeli","year":"1994","unstructured":"Israeli RS, Powell CT, Corr JG, Fair WR, Heston WDW. Expression of the prostate-specific membrane antigen. Cancer Res. 1994;54(7):1807\u201311.","journal-title":"Cancer Res."},{"key":"385_CR15","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res Off J Am Assoc Cancer Res. 1997;3:81\u20135.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res."},{"issue":"2","key":"385_CR16","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2174\/1874471008666150313104212","volume":"8","author":"M Lassmann","year":"2015","unstructured":"Lassmann M, Eberlein U. Radiation dosimetry aspects of 177Lu. Curr Radiopharm. 2015;8(2):139\u201344. https:\/\/doi.org\/10.2174\/1874471008666150313104212.","journal-title":"Curr Radiopharm."},{"issue":"2","key":"385_CR17","first-page":"37S","volume":"40","author":"JA Siegel","year":"1999","unstructured":"Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, et al. MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999;40(2):37S\u201361S.","journal-title":"J Nucl Med."},{"issue":"1","key":"385_CR18","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2967\/jnumed.115.159012","volume":"57","author":"M Ljungberg","year":"2016","unstructured":"Ljungberg M, Celler A, Konijnenberg MW, Eckerman KF, Dewaraja YK, Sj\u00f6green-Gleisner K, et al. MIRD Pamphlet No. 26: Joint EANM\/MIRD Guidelines for quantitative 177Lu SPECT applied for dosimetry of radiopharmaceutical therapy. J Nucl Med. 2016;57(1):151\u201362. https:\/\/doi.org\/10.2967\/jnumed.115.159012.","journal-title":"J Nucl Med."},{"issue":"8","key":"385_CR19","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.2967\/jnumed.111.100123","volume":"53","author":"YK Dewaraja","year":"2012","unstructured":"Dewaraja YK, Frey EC, Sgouros G, Brill AB, Roberson P, Zanzonico PB, et al. MIRD pamphlet No. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy. J Nucl Med. 2012;53(8):1310\u201325. https:\/\/doi.org\/10.2967\/jnumed.111.100123.","journal-title":"J Nucl Med."},{"issue":"11","key":"385_CR20","doi-asserted-by":"publisher","first-page":"112503","DOI":"10.1118\/1.4824318","volume":"40","author":"PA Jackson","year":"2013","unstructured":"Jackson PA, Beauregard J-M, Hofman MS, Kron T, Hogg A, Hicks RJ. An automated voxelized dosimetry tool for radionuclide therapy based on serial quantitative SPECT\/CT imaging. Med Phys. 2013;40(11):112503. https:\/\/doi.org\/10.1118\/1.4824318.","journal-title":"Med Phys."},{"issue":"1","key":"385_CR21","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1102\/1470-7330.2011.0012","volume":"11","author":"J-M Beauregard","year":"2011","unstructured":"Beauregard J-M, Hofman MS, Pereira JM, Eu P, Hicks RJ. Quantitative 177Lu SPECT (QSPECT) imaging using a commercially available SPECT\/CT system. Cancer Imaging. 2011;11(1):56\u201366. https:\/\/doi.org\/10.1102\/1470-7330.2011.0012.","journal-title":"Cancer Imaging."},{"issue":"2","key":"385_CR22","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s00259-009-1216-8","volume":"37","author":"M Sandstr\u00f6m","year":"2010","unstructured":"Sandstr\u00f6m M, Garske U, Granberg D, Sundin A, Lundqvist H. Individualized dosimetry in patients undergoing therapy with 177Lu-DOTA-D-Phe1-Tyr3-octreotate. Eur J Nucl Med Mol Imaging. 2010;37(2):212\u201325. https:\/\/doi.org\/10.1007\/s00259-009-1216-8.","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"9","key":"385_CR23","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1007\/s00259-017-3678-4","volume":"44","author":"A Sundl\u00f6v","year":"2017","unstructured":"Sundl\u00f6v A, Sj\u00f6green-Gleisner K, Svensson J, Ljungberg M, Olsson T, Bernhardt P, et al. Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. Eur J Nucl Med Mol Imaging. 2017;44(9):1480\u20139. https:\/\/doi.org\/10.1007\/s00259-017-3678-4.","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"12","key":"385_CR24","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1007\/s00259-019-04485-3","volume":"46","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, et al. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2019;46(12):2536\u201344. https:\/\/doi.org\/10.1007\/s00259-019-04485-3.","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"33","key":"385_CR25","doi-asserted-by":"publisher","first-page":"55094","DOI":"10.18632\/oncotarget.19049","volume":"8","author":"FC Gaertner","year":"2017","unstructured":"Gaertner FC, Halabi K, Ahmadzadehfar H, K\u00fcrpig S, Eppard E, Kotsikopoulos C, et al. Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer. Oncotarget. 2017;8(33):55094\u2013103. https:\/\/doi.org\/10.18632\/oncotarget.19049.","journal-title":"Oncotarget."},{"key":"385_CR26","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1109\/TNS.2003.817281","volume":"50","author":"C Bai","year":"2003","unstructured":"Bai C, Shao L, Da Silva AJ, Zhao Z. A generalized model for the conversion from CT numbers to linear attenuation coefficients. IEEE Trans Nucl Sci. 2003;50:1510\u20135.","journal-title":"IEEE Trans Nucl Sci."},{"issue":"11","key":"385_CR27","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s00259-008-0875-1","volume":"35","author":"A Schaefer","year":"2008","unstructured":"Schaefer A, Kremp S, Hellwig D, R\u00fcbe C, Kirsch C-M, Nestle U. A contrast-oriented algorithm for FDG-PET-based delineation of tumour volumes for the radiotherapy of lung cancer: derivation from phantom measurements and validation in patient data. Eur J Nucl Med Mol Imaging. 2008;35(11):1989\u201399. https:\/\/doi.org\/10.1007\/s00259-008-0875-1.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"385_CR28","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13550-017-0339-3","volume":"7","author":"M Andersson","year":"2017","unstructured":"Andersson M, Johansson L, Eckerman K, Mattsson S. IDAC-Dose 2.1, an internal dosimetry program for diagnostic nuclear medicine based on the ICRP adult reference voxel phantoms. EJNMMI Res. 2017;7:88.","journal-title":"EJNMMI Res"},{"issue":"14","key":"385_CR29","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1088\/0031-9155\/57\/14\/4501","volume":"57","author":"M Zankl","year":"2012","unstructured":"Zankl M, Schlattl H, Petoussi-Henss N, Hoeschen C. Electron specific absorbed fractions for the adult male and female ICRP\/ICRU reference computational phantoms. Phys Med Biol. 2012;57(14):4501\u201326. https:\/\/doi.org\/10.1088\/0031-9155\/57\/14\/4501.","journal-title":"Phys Med Biol."},{"issue":"2","key":"385_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.icrp.2009.09.001","volume":"39","author":"H-G Menzel","year":"2009","unstructured":"Menzel H-G, Clement C, DeLuca P. ICRP Publication 110. Realistic reference phantoms: an ICRP\/ICRU joint effort. A report of adult reference computational phantoms. Ann ICRP. 2009;39(2):1\u2013164. https:\/\/doi.org\/10.1016\/j.icrp.2009.09.001.","journal-title":"Ann ICRP."},{"issue":"19","key":"385_CR31","doi-asserted-by":"publisher","first-page":"4543","DOI":"10.1088\/0031-9155\/49\/19\/007","volume":"49","author":"S Jan","year":"2004","unstructured":"Jan S, Santin G, Strul D, Staelens S, Assi\u00e9 K, Autret D, et al. GATE: a simulation toolkit for PET and SPECT. Phys Med Biol. 2004;49(19):4543\u201361. https:\/\/doi.org\/10.1088\/0031-9155\/49\/19\/007.","journal-title":"Phys Med Biol."},{"issue":"6","key":"385_CR32","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1109\/TMI.2008.2012036","volume":"28","author":"M Hatt","year":"2009","unstructured":"Hatt M, Cheze le Rest C, Turzo A, Roux C, Visvikis D. A fuzzy locally adaptive Bayesian segmentation approach for volume determination in PET. IEEE Trans Med Imaging. 2009;28(6):881\u201393. https:\/\/doi.org\/10.1109\/TMI.2008.2012036.","journal-title":"IEEE Trans Med Imaging"},{"issue":"2","key":"385_CR33","doi-asserted-by":"publisher","first-page":"141","DOI":"10.11613\/BM.2015.015","volume":"25","author":"D Giavarina","year":"2015","unstructured":"Giavarina D. Understanding Bland Altman analysis. Biochem Medica. 2015;25(2):141\u201351. https:\/\/doi.org\/10.11613\/BM.2015.015.","journal-title":"Biochem Medica."},{"issue":"1","key":"385_CR34","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/MNM.0000000000000606","volume":"38","author":"MP Yadav","year":"2017","unstructured":"Yadav MP, Ballal S, Tripathi M, Damle NA, Sahoo RK, Seth A, et al. Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer. Nucl Med Commun. 2017;38(1):91\u20138. https:\/\/doi.org\/10.1097\/MNM.0000000000000606.","journal-title":"Nucl Med Commun."},{"issue":"13","key":"385_CR35","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1007\/s00259-015-3125-3","volume":"42","author":"L Kabasakal","year":"2015","unstructured":"Kabasakal L, AbuQbeitah M, Ayg\u00fcn A, Yeyin N, Ocak M, Demirci E, et al. Pre-therapeutic dosimetry of normal organs and tissues of 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(13):1976\u201383. https:\/\/doi.org\/10.1007\/s00259-015-3125-3.","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"3","key":"385_CR36","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2967\/jnumed.116.178483","volume":"58","author":"S Okamoto","year":"2017","unstructured":"Okamoto S, Thieme A, Allmann J, D\u2019Alessandria C, Maurer T, Retz M, et al. Radiation dosimetry for 177Lu-PSMA I&T in metastatic castration-resistant prostate cancer: absorbed dose in normal organs and tumor lesions. J Nucl Med. 2017;58(3):445\u201350. https:\/\/doi.org\/10.2967\/jnumed.116.178483.","journal-title":"J Nucl Med."},{"issue":"4","key":"385_CR37","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2967\/jnumed.118.219352","volume":"60","author":"J Violet","year":"2019","unstructured":"Violet J, Jackson P, Ferdinandus J, Sandhu S, Akhurst T, Iravani A, et al. Dosimetry of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes. J Nucl Med. 2019;60(4):517\u201323. https:\/\/doi.org\/10.2967\/jnumed.118.219352.","journal-title":"J Nucl Med."},{"issue":"1","key":"385_CR38","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s00259-015-3174-7","volume":"43","author":"A Delker","year":"2016","unstructured":"Delker A, Fendler WP, Kratochwil C, Brunegraf A, Gosewisch A, Gildehaus FJ, et al. Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43(1):42\u201351. https:\/\/doi.org\/10.1007\/s00259-015-3174-7.","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"1","key":"385_CR39","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/2191-219X-2-49","volume":"2","author":"M Larsson","year":"2012","unstructured":"Larsson M, Bernhardt P, Svensson JB, W\u00e4ngberg B, Ahlman H, Forssell-Aronsson E. Estimation of absorbed dose to the kidneys in patients after treatment with 177Lu-octreotate: comparison between methods based on planar scintigraphy. EJNMMI Res. 2012;2(1):49. https:\/\/doi.org\/10.1186\/2191-219X-2-49.","journal-title":"EJNMMI Res."},{"key":"385_CR40","doi-asserted-by":"publisher","unstructured":"Belli ML, Mezzenga E, Di Iorio V, Celli M, Caroli P, Canali E, et al. A whole body dosimetry protocol for peptide-receptor radionuclide therapy (PRRT): 2D planar image and hybrid 2D+3D SPECT\/CT image methods. J Vis Exp JoVE. 2020;(158). https:\/\/doi.org\/10.3791\/60477.","DOI":"10.3791\/60477"},{"issue":"3","key":"385_CR41","doi-asserted-by":"publisher","first-page":"S108","DOI":"10.1016\/j.ijrobp.2009.02.089","volume":"76","author":"LA Dawson","year":"2010","unstructured":"Dawson LA, Kavanagh BD, Paulino AC, Das SK, Miften M, Li XA, et al. Radiation-associated kidney injury. Int J Radiat Oncol Biol Phys. 2010;76(3):S108\u201315. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.02.089.","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"3","key":"385_CR42","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/j.ijrobp.2009.06.090","volume":"76","author":"JO Deasy","year":"2010","unstructured":"Deasy JO, Moiseenko V, Marks L, Chao KSC, Nam J, Eisbruch A. Radiotherapy dose-volume effects on salivary gland function. Int J Radiat Oncol Biol Phys. 2010;76(3):S58\u201363. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.06.090.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"385_CR43","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40658-018-0210-2","volume":"5","author":"A Sundl\u00f6v","year":"2018","unstructured":"Sundl\u00f6v A, Gustafsson J, Brolin G, Mortensen N, Hermann R, Bernhardt P, et al. Feasibility of simplifying renal dosimetry in 177Lu peptide receptor radionuclide therapy. EJNMMI Phys. 2018;5:12.","journal-title":"EJNMMI Phys."},{"issue":"1","key":"385_CR44","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2967\/jnumed.117.193706","volume":"59","author":"H H\u00e4nscheid","year":"2018","unstructured":"H\u00e4nscheid H, Lapa C, Buck AK, Lassmann M, Werner RA. Dose mapping after endoradiotherapy with 177Lu-DOTATATE\/DOTATOC by a single measurement after 4 days. J Nucl Med. 2018;59(1):75\u201381. https:\/\/doi.org\/10.2967\/jnumed.117.193706.","journal-title":"J Nucl Med."},{"issue":"5","key":"385_CR45","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1007\/s11307-015-0839-3","volume":"17","author":"A Delker","year":"2015","unstructured":"Delker A, Ilhan H, Zach C, Brosch J, Gildehaus FJ, Lehner S, et al. The influence of early measurements onto the estimated kidney dose in [177Lu][DOTA0,Tyr3]octreotate peptide receptor radiotherapy of neuroendocrine tumors. Mol Imaging Biol. 2015;17(5):726\u201334. https:\/\/doi.org\/10.1007\/s11307-015-0839-3.","journal-title":"Mol Imaging Biol."}],"container-title":["EJNMMI Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40658-021-00385-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40658-021-00385-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40658-021-00385-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T09:30:52Z","timestamp":1620207052000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmiphys.springeropen.com\/articles\/10.1186\/s40658-021-00385-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,5]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["385"],"URL":"https:\/\/doi.org\/10.1186\/s40658-021-00385-4","relation":{},"ISSN":["2197-7364"],"issn-type":[{"value":"2197-7364","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,5]]},"assertion":[{"value":"21 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in the patients described herein were in accordance with the ethical standards of the Institutional and\/or National Research Ethics Committees and with the 1964 Helsinki Declaration and its later amendments, or with comparable ethical standards. This report does not include any animal studies. Written informed consent was obtained from all study participants","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients have given written consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}